retatrutide regulatory approval The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, My thoughts on Retatrutide 🤔🤔

Beyond Weight Loss: The Longevity Revolution While GLP-1 medications like tirzepatide have gained widespread attention for their remarkable weight loss results, emerging research reveals their potential to address aging-related diseases and expand healthy lifespan

Retatrutide handles appetite, digestion, and systemic metabolism

Retatrutide is still investigational and is not yet FDA-approved

International researchers examined Swedish health records of almost 95,000 people with a diagnosis of depression or anxiety who were also taking various diabetes medications between 2009 and 2022

Based on the populations studied in clinical trials to date, retatrutide has been investigated primarily in adults living with obesity defined as a body mass index (BMI) of 30 kg/m or above as well as in those who are overweight (BMI 27 kg/m or above) with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or dyslipidaemia